Equities analysts predict that Lantheus Holdings Inc (NASDAQ:LNTH) will report $0.31 earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Lantheus’ earnings. Lantheus posted earnings of $0.29 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 6.9%. The firm is expected to report its next earnings report on Tuesday, February 18th.
According to Zacks, analysts expect that Lantheus will report full-year earnings of $1.11 per share for the current year. For the next year, analysts forecast that the company will post earnings of $1.26 per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that that provide coverage for Lantheus.
Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Thursday, October 31st. The medical equipment provider reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.07. The company had revenue of $85.80 million for the quarter, compared to analysts’ expectations of $83.82 million. Lantheus had a net margin of 10.02% and a return on equity of 46.58%. Lantheus’s revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company posted $0.24 EPS.
In other news, CEO Mary Anne Heino sold 15,590 shares of the company’s stock in a transaction on Friday, September 20th. The shares were sold at an average price of $25.81, for a total value of $402,377.90. Following the completion of the sale, the chief executive officer now owns 582,294 shares of the company’s stock, valued at approximately $15,029,008.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael P. Duffy sold 7,500 shares of the stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $23.74, for a total transaction of $178,050.00. Following the transaction, the senior vice president now directly owns 131,390 shares in the company, valued at approximately $3,119,198.60. The disclosure for this sale can be found here. Insiders have sold 55,868 shares of company stock worth $1,338,353 over the last quarter. Company insiders own 2.60% of the company’s stock.
Large investors have recently modified their holdings of the stock. New York State Teachers Retirement System grew its stake in shares of Lantheus by 6.3% during the second quarter. New York State Teachers Retirement System now owns 48,753 shares of the medical equipment provider’s stock valued at $1,380,000 after buying an additional 2,874 shares during the last quarter. James Investment Research Inc. grew its holdings in shares of Lantheus by 4.6% in the second quarter. James Investment Research Inc. now owns 29,805 shares of the medical equipment provider’s stock worth $843,000 after purchasing an additional 1,300 shares during the last quarter. First Quadrant L P CA grew its holdings in shares of Lantheus by 330.2% in the second quarter. First Quadrant L P CA now owns 16,685 shares of the medical equipment provider’s stock worth $472,000 after purchasing an additional 12,807 shares during the last quarter. Arizona State Retirement System increased its stake in shares of Lantheus by 1.3% in the second quarter. Arizona State Retirement System now owns 60,218 shares of the medical equipment provider’s stock worth $1,704,000 after buying an additional 752 shares during the period. Finally, Strs Ohio purchased a new position in shares of Lantheus in the second quarter worth $489,000. Institutional investors own 99.29% of the company’s stock.
Shares of LNTH opened at $20.15 on Wednesday. The stock’s 50-day simple moving average is $20.31 and its 200 day simple moving average is $23.47. The stock has a market capitalization of $820.28 million, a price-to-earnings ratio of 21.44, a price-to-earnings-growth ratio of 1.74 and a beta of 1.43. The company has a debt-to-equity ratio of 1.84, a quick ratio of 2.08 and a current ratio of 2.59. Lantheus has a 52-week low of $13.82 and a 52-week high of $29.80.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
See Also: Price Target
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.